Status:
COMPLETED
Assessment Of Safety Of UK-390,957
Lead Sponsor:
Pfizer
Conditions:
Ejaculation
Eligibility:
MALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
Eligibility Criteria
Inclusion
- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV
Exclusion
- No drug related serious adverse events
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
1058 Patients enrolled
Trial Details
Trial ID
NCT00219609
Start Date
January 1 2005
End Date
March 1 2006
Last Update
November 7 2012
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tucson, Arizona, United States
2
Pfizer Investigational Site
Anaheim, California, United States
3
Pfizer Investigational Site
Atherton, California, United States
4
Pfizer Investigational Site
Beverly Hills, California, United States